OHSU

IRB #

IRB00009526

Title

A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib

Principal Investigator

Willscott Naugler

Study Purpose

To examine a new medication called regorafenib when used in those with hepatocellular carcinoma (HCC) who have failed previous treatment with sorafenib.

Medical Condition(s)

Hepatocellular Carcinoma (HCC)

Eligibility Criteria

Males and Females, aged 18 and older, with HCC, who have taken and failed treatment with sorafenib in the past.

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

The study consists of "cycles." These cycles are 4 weeks long - or 28 days. There are several cycles in this study. Subjects will continue to complete these cycles indefinitely until their cancer gets worse or the study ends for another reason.

Minors Included

No

Contact

Kathy Bacon - 503-418-8332

Sponsor

Bayer Healthcare Pharmaceuticals, Inc

Recruitment End

11/28/2014

Compensation Provided

Yes

Compensation

Subjects will be compensated $60 for each study visit completed. If a subject should leave the study early they will only receive compensation for the visits completed in full.


Go Back